HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

HERON THERAPEUTICS, INC. /DE/

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$0.36−0.00 (-0.03%)

Close on Oct 19, 2026

Market cap: $68.69M
P/E (TTM): –
Dividend yield: –

HERON THERAPEUTICS, INC. /DE/ balance sheet

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Cash & Equivalents	29	26	29	15	91	105	72	32	145	13	75	73	72	54	18	2.11	7.59	9.97
Short-Term Investments	18	33	52	69	67	103	319	301	–	–	–	–	–	–	–	–	–	–
Cash & Short-Term Investments	47	59	80	85	158	209	391	332	172	51	131	73	72	54	18	2.11	7.59	9.97
Receivables	90	79	60	52	35	42	40	65	42	1.96	–	–	–	–	–	0.11	–	–
Inventory	93	53	42	55	48	42	25	39	10	5.34	–	–	–	–	–	–	–	–
Prepaid Expenses & Other	9.10	18	6.12	14	13	22	23	11	3.70	3.71	3.59	1.06	0.64	0.58	0.27	0.28	–	–
Total Current Assets	238	209	189	205	254	314	479	447	228	62	135	74	73	54	18	2.50	–	–
Property, Plant & Equipment	12	15	20	22	24	23	20	15	5.98	5.08	3.05	2.82	2.88	1.75	1.08	0.36	–	–
Gross Property, Plant & Equipment	25	33	37	36	37	34	28	23	14	12	8.60	7.65	7.16	6.16	5.36	–	–	–
Accumulated Depreciation	-13	-18	-17	-14	-13	-11	-8.03	-8.10	-7.86	-6.61	-5.55	-4.83	-4.27	-4.41	-4.28	–	–	–
Construction in Progress	1.70	2.60	6.30	5.40	16	14	14	10	2.00	1.70	0.20	–	–	0.78	0.72	–	–	–
Operating Lease Right-of-Use Assets	0	2.79	5.44	7.65	9.83	16	14	14	–	–	–	–	–	–	–	–	–	–
Other Long-Term Assets	5.41	6.48	8.13	16	18	0.35	0.35	0.25	0.26	0.26	0.05	0.13	0.13	0.13	0.13	0.05	–	–
Total Assets	256	233	223	251	306	354	513	462	234	67	138	77	76	56	19	2.91	–	–
Accounts Payable	8.99	12	3.24	3.23	3.80	0.53	2.76	17	19	6.81	3.30	2.55	1.26	1.91	1.01	0.16	–	–
Accrued Expenses	–	–	–	–	–	–	–	–	–	–	–	–	4.70	1.75	1.50	0.46	–	–
Current Portion of Leases	0	3.04	3.08	2.69	2.42	3.00	1.93	–	–	–	–	–	–	–	–	–	–	–
Deferred Revenue (Current)	–	–	–	–	–	–	–	–	2.76	1.10	–	–	–	–	–	0.24	–	–
Total Current Liabilities	96	91	80	82	71	103	97	92	103	39	20	14	6.99	4.15	3.69	1.56	–	–
Long-Term Leases	0	–	2.80	5.50	8.00	15	12	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	0	3.04	5.88	8.19	10	18	14	15	–	–	–	–	–	–	–	–	–	–
Other Long-Term Liabilities	4.81	0.62	0.24	0.24	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	242	267	256	237	228	117	109	92	103	89	20	14	6.99	4.15	3.69	1.60	–	–
Preferred Stock	1.05	0	–	–	–	–	–	–	–	0	0	0	0	0	–	–	–	–
Common Stock	1.88	1.52	1.50	1.19	1.02	0.91	0.90	0.78	0.65	0.39	0.36	0.29	0.24	0.15	2.00	0.40	–	–
Additional Paid-In Capital	1,951	1,884	1,871	1,808	1,690	1,628	1,568	1,330	914	564	531	378	308	235	174	149	–	–
Retained Earnings	-1,940	-1,920	-1,906	-1,795	-1,613	-1,393	-1,165	-961	-783	-586	-413	-315	-239	-184	-160	-148	–	–
Comprehensive Income & Other	0.00	0.01	0.01	-0.02	-0.01	0.26	0.09	-0.09	-0.01	-0.02	-0.04	–	–	–	–	–	–	–
Shareholders' Equity	14	-34	-34	14	78	236	404	370	131	-21	118	63	69	52	16	1.32	6.80	–
Total Equity	14	-34	-34	14	78	236	404	370	131	-21	118	63	69	52	16	1.32	6.80	–
Total Liabilities & Equity	256	233	223	251	306	354	513	462	234	67	138	77	76	56	19	2.91	–	–
Shares Outstanding(shares)	188	152	150	119	102	91	90	78	65	0.04	36	29	24	15	10	2.01	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 70.1%
Operating margin: -7.2%
Net margin: -22.5%
Return on equity, FY2025: 209.1%

Financial strength

Current ratio: 2.49
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 22.5%

Valuation

P/E ratio: –
Price to sales: 0.45
Price to book: 9.94
Dividend yield: –